<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>General toxicity of cyclophosphamide in rheumatic diseases</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">General toxicity of cyclophosphamide in rheumatic diseases</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">General toxicity of cyclophosphamide in rheumatic diseases</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Megan B Clowse, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">W Joseph McCune, MD, MACR</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel E Furst, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Siobhan M Case, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 16, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">Cyclophosphamide</a> (CYC) is an alkylating agent that was introduced into clinical practice as a chemotherapeutic agent but has also been used to treat a number of systemic autoimmune diseases. It is generally used in cases of life- or organ-threatening rheumatic diseases, such as antineutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis or systemic lupus erythematosus (SLE) with renal or central nervous system involvement.</p><p>CYC is also associated with a variety of toxicities that should lead clinicians to consider less toxic alternative medications whenever possible. While much of our knowledge about the toxicity of CYC has been extrapolated from its use in oncology and historical studies, contemporary use of CYC often results in a lower cumulative dose, making toxicity likely lower than prior reports.</p><p>Historically, patients were often treated with daily oral CYC for several years at a time. This type of oral CYC dosing could result in exposure to more than 36 g of CYC over a year of therapy and 50 to 150 g over a lifetime of vasculitis management [<a href="#rid1">1</a>]. Contemporary regimens are more likely to include intermittent intravenous dosing of CYC for a three- to six-month period, followed by a less-toxic immunosuppressant. Typical intravenous dosing of 0.75 to 1 g/m<sup>2</sup> over a six-month course results in 4.5 to 9 g, depending on the size of the patient [<a href="#rid2">2</a>]. Alternatively, the Euro-Lupus protocol for lupus nephritis results in just 3 g of CYC dosed over a three-month period [<a href="#rid3">3</a>]. Nonetheless, patients who require multiple courses of therapy, particularly with oral CYC, may ultimately reach cumulative doses associated with significant, long-term toxicity. Administration to a female patient of several pulse CYC regimens over the course of her illness (eg, for recurrent lupus nephritis) poses a risk of premature ovarian insufficiency particularly for women in their 30s and 40s, even if the risk from a single treatment is relatively small.</p><p>This topic will provide an overview of the mechanism of action and major toxicities associated with CYC use for the treatment of systemic rheumatic diseases. General principles of the use of CYC for rheumatic diseases as well as the pharmacology of the drug are discussed separately. (See  <a class="medical medical_review" href="/d/html/7963.html" rel="external">"General principles of the use of cyclophosphamide in rheumatic diseases"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">MECHANISM OF ACTION</span><span class="headingEndMark"> — </span>Alkylating agents exert their biologic activity via covalent binding and crosslinking of a variety of macromolecules including deoxyribonucleic acid (DNA), ribonucleic acid (RNA), and proteins. DNA crosslinking, probably the most important biologic action of these drugs, impairs DNA replication and transcription, ultimately leading either to cell death or to altered cellular function [<a href="#rid4">4</a>].</p><p>The degree of inhibition of immune function is dependent upon the dose and duration of therapy. Alkylating agents are cytotoxic. Absolute lymphopenia is frequently seen following their administration, with reductions in the number of B cells and T cells of both CD4+ and CD8+ types [<a href="#rid5">5,6</a>]. The ratio of circulating T cells and B cells may also be affected [<a href="#rid7">7</a>]. Repeated pulses of CYC may be associated with B cell depletion to &lt;5 CD20 cells/mm<sup>3</sup> [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H4"><span class="h1">TOXICITY</span><span class="headingEndMark"> — </span>The alkylating agents share a number of potentially severe side effects including bone marrow suppression, increased susceptibility to infection, gonadal toxicity, teratogenicity, bladder toxicity, hyponatremia, and an increased risk of malignancy.</p><p>The cumulative dose of <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> (CYC) is a major risk factor for toxicity. Thus, strategies that reduce the cumulative dose and duration of exposure can minimize long-term risks. One such strategy is to use intermittent pulse CYC regimens rather than daily oral therapy, which can result in a 60 percent or greater decrease in the cumulative dose. Also, changing CYC for another less toxic medication after remission induction is achieved is another strategy to limit exposure. The following examples are illustrative:</p><p class="bulletIndent1"><span class="glyph">●</span>In a trial of sequential therapy for lupus nephritis, patients began with pulse CYC for six months, followed by random assignment to one of three different regimens: continued CYC, <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil, or <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> [<a href="#rid8">8</a>]. By switching from CYC to another drug, the risk for infection decreased from 77 percent to 29 to 32 percent. Prolonged amenorrhea decreased from 32 percent to 6 to 8 percent. (See  <a class="medical medical_review" href="/d/html/3059.html" rel="external">"Lupus nephritis: Initial and subsequent therapy for focal or diffuse lupus nephritis", section on 'Cyclophosphamide-based regimen'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the CYCAZAREM trial, a study of patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), orally administered CYC (plus glucocorticoids) was given for three to six months for remission induction, and then patients were randomly assigned to discontinue CYC in favor of the less toxic <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> or to continue CYC [<a href="#rid9">9</a>]. At 18 months, the numbers of disease flares in the two treatment groups did not differ, but those patients in the azathioprine group were spared months of CYC exposure, presumably incurring lower long-term risks of cancer, infertility, and other side effects. (See  <a class="medical medical_review" href="/d/html/3105.html" rel="external">"Granulomatosis with polyangiitis and microscopic polyangiitis: Induction and maintenance therapy", section on 'Choice of maintenance therapy'</a>.)</p><p></p><p>Because the daily and intermittent intravenous administrations of CYC are not therapeutically equivalent in some settings, the decision about the route of administration and duration of therapy, whenever possible, should be based upon data available for a specific disease.</p><p>In addition to the cumulative dose, the toxicity of CYC is also affected by genetic polymorphisms of the cytochrome P450 enzyme system [<a href="#rid10">10</a>]. As an example, in one study of 62 patients with lupus nephritis, those treated with CYC who were either homozygous or heterozygous for the cytochrome P450 variant 2C19*2 demonstrated a significantly lower risk of ovarian failure (from 80 to 35 percent) [<a href="#rid11">11</a>] (see <a class="local">'Gonadal toxicity'</a> below). However, the genotypes resulting in lower exposure also correlated with an increased risk of progression to end-stage kidney disease. Another study of 196 people with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis found a higher frequency of leukopenia if a variant CYP2C9 was present (odds ratio [OR] 2.09) [<a href="#rid12">12</a>]. Assessment of cytochrome P450 variants is not performed routinely in clinical practice. These findings, however, emphasize the variability in susceptibility to the effects of alkylating agent therapy. They also underscore the importance of careful monitoring for adverse effects. (See  <a class="medical medical_review" href="/d/html/7963.html" rel="external">"General principles of the use of cyclophosphamide in rheumatic diseases", section on 'Intermittent (pulse) cyclophosphamide'</a>.)</p><p class="headingAnchor" id="H5"><span class="h2">Hematologic toxicity</span><span class="headingEndMark"> — </span>One of the most serious short-term side effects of CYC relates to the induction of cytopenias. Hematologic toxicity becomes more common with increasing doses and is also more likely to occur with a longer duration of use. In a meta-analysis of trials of CYC for idiopathic membranous nephropathy and lupus nephritis, leukopenia was reported in 46 out of 276 (17 percent) and 12 out of 90 (13 percent) patients, respectively [<a href="#rid13">13,14</a>]. Granulocytes and lymphocytes are most likely to be affected first (sometimes within days to a few weeks of treatment), followed by the platelet count and hematocrit. The total white blood cell count, as well as either the absolute neutrophil or the lymphocyte lines, can be affected. The tendency of CYC to cause lymphopenia is enhanced by the concomitant use of high doses of glucocorticoids. In view of the demargination of neutrophils that occurs with high-dose glucocorticoids, a white blood cell count below 4000/mm<sup>3</sup> in this situation has been reported to be associated with substantial immunosuppression even if the absolute neutrophil count remains &gt;1500/mm<sup>3</sup>.</p><p>In order to detect impending and potentially dangerous bone marrow toxicity, patients treated with daily oral CYC should have complete blood counts checked approximately every two weeks for as long as they receive this medication. Suppression of the total white blood cell count is not an aim of treatment with daily oral CYC and should be avoided, with dose adjustments as the total white blood count begins to fall. Patients receiving intravenous pulse CYC, usually administered on a monthly basis, develop leukopenic nadirs in a predictable fashion 7 to 14 days after administration, with the nadir of the lymphocyte count occurring approximately day 7 and that of the granulocyte count approximately day 14 [<a href="#rid6">6</a>].</p><p>Titrating the dose of monthly (but not biweekly) infusions of CYC to achieve a nadir of approximately 3000 to 3500 white blood cells per mm<sup>3</sup> with an absolute neutrophil count of greater than 1000 to 1500 has been used as a method of dose adjustment. Bone marrow recovery is usually evident by 21 days. Monitoring of blood counts during treatment with CYC is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/7963.html" rel="external">"General principles of the use of cyclophosphamide in rheumatic diseases", section on 'Monitoring of intermittent CYC dosing'</a>.)</p><p>Although it is easier in clinical practice to monitor white cell counts with intravenous administration of CYC given the predictable nadir, there does not seem to be a significant difference in the frequency of severe leukopenic events with oral versus intravenous administration. As an example, in a review of 212 systemic lupus erythematosus (SLE) patients with diffuse proliferative lupus nephritis treated with CYC, there was no significant difference in the number of severe leukopenic events (defined as white blood cell counts &lt;2000/mm<sup>3</sup>) among patients treated with oral versus intravenous CYC (5 versus 7 percent, respectively) [<a href="#rid15">15</a>]. The CYCLOPS study, which compared oral with intravenous CYC for the treatment of ANCA-associated vasculitis, found fewer episodes of neutropenia in the intravenous CYC arm [<a href="#rid2">2</a>]. However, this lower rate of neutropenic events was not associated with fewer infectious complications of treatment.</p><p class="headingAnchor" id="H7"><span class="h2">Infection</span><span class="headingEndMark"> — </span>CYC can predispose to bacterial, opportunistic, and viral infections [<a href="#rid16">16-22</a>]. CYC increases the risk of infection by inducing bone marrow depression, resulting in neutropenia and/or lymphopenia, and by interfering with normal neutrophil and lymphocyte function even in the absence of count reductions.</p><p>Patients receiving CYC who become neutropenic (absolute neutrophil count less than 1500/microL), especially those who are treated concomitantly with high doses of glucocorticoids, are at particular risk for infection [<a href="#rid16">16,22</a>]. As an example, a study including 143 patients with SLE found that infection occurred in 45 percent of CYC-treated patients compared with 12 percent of those treated with glucocorticoids alone [<a href="#rid22">22</a>]. Bacterial infections were the most common, followed by opportunistic infections and herpes zoster. Multiple meta-analyses suggest the risk for infection during CYC therapy with glucocorticoids is between 20 and 40 percent [<a href="#rid13">13,14,23</a>].</p><p>The effect of obesity on the safety of calculating bolus CYC dose according to total versus ideal body weight remains controversial, but the weight of the evidence from the cancer literature suggests that dose reduction may not be necessary to reduce the risk of neutropenia and/or infection. In several studies, the incidence of febrile neutropenia was not higher in patients with obesity treated according to total body weight [<a href="#rid24">24</a>], and reviews and guidelines suggest for cancer treatment that doses calculated according to full body weight or partially adjusted toward lean body weight should be used [<a href="#rid25">25,26</a>].</p><p>Major bacterial or fungal infections can occur in the absence of neutropenia. This has been estimated to occur in 5 to 21 percent of patients treated with CYC for GPA or lupus nephritis [<a href="#rid15">15,16,19,27</a>]. Concomitant use of glucocorticoids is thought to be a major risk factor for fungal infection, as well [<a href="#rid16">16</a>].</p><p>Infection with <em>Pneumocystis jirovecii</em> is a known complication of treatment with CYC, particularly when administered in combination with glucocorticoids [<a href="#rid28">28</a>]. As a result, prophylaxis is indicated for almost all patients on CYC. Prophylactic therapy for <em>Pneumocystis</em> pneumonia is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/7963.html" rel="external">"General principles of the use of cyclophosphamide in rheumatic diseases", section on 'Prophylaxis for Pneumocystis jirovecii pneumonia infection'</a> and  <a class="medical medical_review" href="/d/html/1393.html" rel="external">"Treatment and prevention of Pneumocystis pneumonia in patients without HIV", section on 'Prophylaxis'</a>.)</p><p>There is also substantially increased risk for herpes zoster infection with CYC treatment. The incidence of zoster in different trials of vasculitis and lupus has ranged from 8 to 33 percent [<a href="#rid16">16,19,27</a>]. In one large trial of GPA, most zoster events did not occur during the periods of most intensive immunosuppression but rather occurred after patients had discontinued CYC and <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>, suggesting the possibility of an immune reconstitution syndrome [<a href="#rid29">29</a>]. The increased risk of herpes zoster has also been demonstrated in patients with SLE treated with CYC. A population-based study using medical records found an adjusted OR for developing zoster of 3.76 to 4.64 for oral and intravenous CYC, respectively [<a href="#rid30">30</a>]. In a study of childhood SLE, CYC increased the risk of herpes zoster with an adjusted OR of 4.1 [<a href="#rid31">31</a>]. In both of these studies, prednisone use was also an independent predictor of herpes zoster with an OR between 6.3 and 6.7. Immunization with recombinant adjuvanted zoster vaccine would optimally be accomplished prior to CYC administration, although this may not be practical. This is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/8343.html" rel="external">"Vaccination for the prevention of shingles (herpes zoster)"</a>.)</p><p>CYC therapy is associated with increased susceptibility to infection with or reactivation of human papilloma virus (HPV) based on the observed incidence of cervical intraepithelial neoplasia in women treated with CYC [<a href="#rid32">32</a>]. Age-appropriate screening for cervical cancer and HPV infection in women is discussed separately. (See  <a class="medical medical_review" href="/d/html/7963.html" rel="external">"General principles of the use of cyclophosphamide in rheumatic diseases", section on 'Laboratory and clinical testing'</a> and  <a class="medical medical_review" href="/d/html/7575.html" rel="external">"Screening for cervical cancer in resource-rich settings"</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Gonadal toxicity</span><span class="headingEndMark"> — </span>CYC is toxic to both ovaries and testes. The incidence of gonadal dysfunction is dependent upon age, sex, and cumulative CYC dose [<a href="#rid33">33,34</a>]. (See  <a class="medical medical_review" href="/d/html/7455.html" rel="external">"Effects of cytotoxic agents on gonadal function in adult men"</a>.)</p><p class="headingAnchor" id="H9"><span class="h3">Female gonadal toxicity</span><span class="headingEndMark"> — </span>In women, CYC may lead to infertility and premature menopause (premature ovarian failure [POF]). Treatment-induced damage includes depletion of ovarian follicles and shrinkage and fibrosis of the ovaries. Some patients who develop amenorrhea during treatment may subsequently recover ovarian function. Conversely, some women with apparent preservation of ovarian function during and after treatment may develop premature ovarian insufficiency years later. Women treated before the age of 25 are at lower risk of infertility than those treated after the age of 30 [<a href="#rid18">18,33,35-39</a>]. The cumulative total CYC dose is an independent risk factor for ovarian toxicity, regardless of how the medication is administered.</p><p>The following data illustrate these points:</p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis including 1388 women (mean age 27.7) receiving intravenous CYC for systemic rheumatic diseases found that sustained amenorrhea occurred in 273 women (19.7 percent) [<a href="#rid40">40</a>]. The rate of sustained amenorrhea was positively correlated with increasing cumulative CYC and was unlikely in patients with a cumulative CYC dose &lt;5 g.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A report of 84 women who were menstruating prior to intravenous CYC administration for SLE or vasculitis also demonstrated the importance of age [<a href="#rid37">37</a>]. Chronic amenorrhea did not develop in any of the 22 women younger than 26 years of age but occurred 14 of the 20 women (70 percent) older than age 35.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A study of women receiving the lower-dose regimen of CYC used for SLE (of six 500 mg intravenous pulses every two weeks) did not reveal changes in ovarian function as assessed by anti-Müllerian hormone (AMH) levels compared with never-treated patients [<a href="#rid41">41</a>].</p><p></p><p>Some women who are treated successfully with CYC are able to conceive and deliver healthy children [<a href="#rid36">36,37,42</a>]. In a study of 85 women treated with intravenous CYC for rheumatologic diseases, 16 women became pregnant after completing treatment [<a href="#rid37">37</a>]. The outcomes of 16 pregnancies in these women included 10 healthy babies, three spontaneous miscarriages, and three pregnancy terminations (two for anomalies and one for an SLE flare). In another study of women with SLE, 80 percent of those who tried to conceive were pregnant after 12 months, regardless of whether they had received CYC or not; the authors estimated that &lt;10 percent of study participants had received gonadotropin-releasing hormone (GnRH)-agonist cotherapy with CYC [<a href="#rid43">43</a>].</p><p>Another study evaluated the impact of prior intravenous CYC exposure on pregnancy outcomes in 535 women with SLE in Saudi Arabia, and found that the rate of live birth was not significantly different among women with and without prior CYC exposure (68 percent and 71 percent, respectively) [<a href="#rid44">44</a>]. Despite having the same rate of active lupus nephritis during pregnancy in each group (around 30 percent), significantly more pregnancies were delivered preterm to women with prior CYC exposure (41 percent) than to women without prior CYC exposure (23 percent).</p><p>Because women may remain fertile during therapy with CYC, steps to avoid pregnancy during treatment are essential. Counseling about the need for effective contraception during CYC administration is discussed separately. (See  <a class="medical medical_review" href="/d/html/7963.html" rel="external">"General principles of the use of cyclophosphamide in rheumatic diseases", section on 'Contraception'</a> and  <a class="medical medical_review" href="/d/html/5459.html" rel="external">"Contraception: Counseling and selection", section on 'Special populations'</a>.)</p><p class="headingAnchor" id="H11"><span class="h3">Male gonadal toxicity</span><span class="headingEndMark"> — </span>CYC causes a decrease in sperm count and with higher doses and treatment duration can lead to irreversible azoospermia [<a href="#rid45">45,46</a>]. Testicular injury is reported to occur in boys and men after 7 to 9 g of CYC and to occur more often with comparable doses of intravenous versus oral CYC; recovery is documented in some patients [<a href="#rid47">47</a>]. As an example, the reproductive function was studied in 31 male patients with Behçet syndrome during treatment with CYC and/or <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> [<a href="#rid48">48</a>]. Severe oligospermia or azoospermia occurred in 13 of 17 men treated with CYC but occurred in none of the patients treated with colchicine alone [<a href="#rid48">48</a>]. Nevertheless, many men have fathered children after alkylating agent therapy [<a href="#rid49">49,50</a>].</p><p>Men with SLE appear to have diminished sperm quality compared with healthy controls [<a href="#rid51">51</a>]. A study of 35 men with SLE found that 86 percent of those with prior CYC treatment had very poor sperm quality, compared with 45 percent of the men without prior CYC [<a href="#rid51">51</a>]. The average duration between CYC and sperm analysis was five years and all CYC was given after the first ejaculation.</p><p>The effects of CYC on gonadal function in men as well as the prevention of gonadal toxicity are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/7455.html" rel="external">"Effects of cytotoxic agents on gonadal function in adult men", section on 'Cyclophosphamide'</a> and  <a class="medical medical_review" href="/d/html/7455.html" rel="external">"Effects of cytotoxic agents on gonadal function in adult men"</a> and  <a class="medical medical_review" href="/d/html/15904.html" rel="external">"Effects of antiinflammatory and immunosuppressive drugs on gonadal function and teratogenicity in men with rheumatic diseases", section on 'Cyclophosphamide'</a> and  <a class="medical medical_review" href="/d/html/7963.html" rel="external">"General principles of the use of cyclophosphamide in rheumatic diseases", section on 'Infertility risk'</a>.)</p><p class="headingAnchor" id="H13"><span class="h2">Teratogenicity</span><span class="headingEndMark"> — </span>CYC is associated with congenital (or fetal) malformations and should be avoided during the first 10 weeks of gestation, when the fetus is most susceptible to teratogens  (<a class="graphic graphic_figure graphicRef56642" href="/d/graphic/56642.html" rel="external">figure 1</a>). However, CYC has been used in life-threatening circumstances in the mother, especially in the second and third trimesters [<a href="#rid52">52-55</a>]. The frequency of congenital anomalies is difficult to estimate, as many conceptions exposed to CYC result in a pregnancy loss. In two cohorts totaling 86 live births with CYC exposure, 23 (26.7 percent) were born with a congenital malformation [<a href="#rid56">56</a>].</p><p>The risk of congenital anomaly is greatest with exposure during the first trimester. Eleven case reports of women who received CYC for cancer or lupus therapy during the first trimester showed a pattern of anomalies labeled "<a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> embryopathy" [<a href="#rid57">57-60</a>]. These infants had multiple abnormalities, including growth restriction, ear and facial abnormalities, absence of digits, and hypoplastic limbs. Of the six pregnancies that resulted in surviving children, at least three had severe developmental delay. One twin pregnancy with CYC exposure for acute lymphocytic leukemia resulted in two live infants who were small for dates and who required intubation after delivery. One of these infants recovered fully and developed normally. The other had significant congenital abnormalities, had developmental and cognitive problems, and developed both papillary thyroid cancer and neuroblastoma by the age of 14 [<a href="#rid61">61</a>].</p><p>Exposure to CYC during the second and third trimester may be associated with low birthweight and with neonatal pancytopenia. In a study of women diagnosed with breast cancer during pregnancy, all 24 pregnancies with second- and third-trimester exposure to CYC resulted in live births [<a href="#rid62">62</a>]. A study of fetal brain growth after second and third trimester dosing of chemotherapy (anthracyclines and CYC-based regimens) did not reveal smaller brain size in infants, nor developmental changes at 18 months of age compared with infants born to healthy women [<a href="#rid63">63</a>].</p><p>When CYC is required mid-pregnancy to treat a life-threatening lupus flare, however, the survival of the fetus is less likely [<a href="#rid55">55,64</a>] (see  <a class="medical medical_review" href="/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation", section on 'Cyclophosphamide'</a>). The increasing availability of alternative therapies has reduced the need for this approach.</p><p>Men should also practice effective birth control to avoid conception during CYC treatment. Although there are no established human data, exposure of male rats to CYC is associated with increased rates of fetal loss and malformations [<a href="#rid65">65</a>]. If sperm are to be collected for cryopreservation, they should be obtained prior to the first dose of CYC, as genetic damage from CYC can occur in sperm anywhere along the developmental pathway, especially those near maturity [<a href="#rid66">66</a>]. (See  <a class="medical medical_review" href="/d/html/15904.html" rel="external">"Effects of antiinflammatory and immunosuppressive drugs on gonadal function and teratogenicity in men with rheumatic diseases", section on 'Cyclophosphamide'</a>.)</p><p>As noted above, men previously treated with CYC have fathered successful pregnancies. Chromosomal abnormalities have been noted in patients after CYC exposure, but it is unclear if similar changes occur in eggs or sperm [<a href="#rid67">67</a>]. One man with prior CYC therapy fathered an infant with tetralogy of Fallot and syndactyly of the toes [<a href="#rid68">68</a>]. Four pregnancies after CYC therapy for SLE resulted in four live births. One baby was delivered preterm, and another was small for gestational age [<a href="#rid42">42</a>]. The risk of congenital anomalies in offspring to parents previously treated with these agents is unknown.</p><p class="headingAnchor" id="H14"><span class="h2">Malignancy</span><span class="headingEndMark"> — </span>Patients with rheumatoid arthritis (RA), SLE, and other systemic autoimmune diseases are at increased risk of developing lymphoma independent of treatment. However, the administration of CYC enhances this risk, and an increased risk of leukemia, skin cancer, cervical cancer, and other malignancies has been reported [<a href="#rid16">16,69-72</a>]. Mechanisms of alkylating agent-induced malignancy include direct chromosomal damage and decreased immune surveillance. The duration of therapy is an important risk factor, with the incidence being greatest in patients treated for more than two to three years [<a href="#rid71">71</a>].</p><p>A population-based cohort study found that 195 patients with CYC therapy for ANCA-associated vasculitis had higher than expected rates of malignancy in long-term follow-up (median 8 years, interquartile range [IQR] 4.0 to 11.9 years) [<a href="#rid73">73</a>]. The risk was highest for patients with a cumulative dose of CYC over 36 g with an age- and sex-standardized incidence ratio of 3.4 (95% CI 1.5-6.4) for all malignancies other than squamous cell carcinomas. Patients with a cumulative dose of CYC below 10 g had a higher risk for squamous cell carcinomas, but not other malignancies.</p><p>Patients with previous exposure to CYC are at increased risk for hematologic malignancies. Myelodysplastic syndrome may occur in up to 8 percent of patients with GPA after CYC and in 13 percent of such patients with a cumulative dose over 100 g [<a href="#rid74">74</a>]. Myeloproliferative disease, including acute leukemia, non-Hodgkin lymphoma (NHL), and multiple myeloma, occurred in 5 of 119 patients within the first decade after treatment with CYC, compared with one case of chronic lymphocytic leukemia in 119 RA patients without a history of use of CYC [<a href="#rid71">71</a>]. (See  <a class="medical medical_review" href="/d/html/4506.html" rel="external">"Therapy-related myeloid neoplasms: Epidemiology, causes, evaluation, and diagnosis"</a>.)</p><p class="headingAnchor" id="H15"><span class="h2">Bladder toxicity</span><span class="headingEndMark"> — </span>Both hemorrhagic cystitis and bladder cancer are associated with CYC therapy because of exposure of the bladder to the acrolein, a toxic metabolite of CYC (see  <a class="medical medical_review" href="/d/html/2829.html" rel="external">"Chemotherapy and radiation-related hemorrhagic cystitis in cancer patients", section on 'Cyclophosphamide'</a> and  <a class="medical medical_review" href="/d/html/2989.html" rel="external">"Clinical presentation, diagnosis, and staging of bladder cancer"</a>). Prevention of bladder toxicity associated with CYC use for systemic rheumatic diseases is discussed separately. (See  <a class="medical medical_review" href="/d/html/7963.html" rel="external">"General principles of the use of cyclophosphamide in rheumatic diseases", section on 'Prevention of drug-induced cystitis'</a>.)</p><p class="headingAnchor" id="H429284814"><span class="h3">Hemorrhagic cystitis</span><span class="headingEndMark"> — </span>The risk of hemorrhagic cystitis in patients receiving CYC as an immunosuppressive agent for rheumatologic disease varies according to the route of administration. It is highest with continuous daily oral administration because the duration of treatment and total cumulative exposure are higher as compared with intermittent intravenous dosing regimens [<a href="#rid75">75</a>]. In three large cohort studies including patients with GPA, the incidence of hemorrhagic cystitis ranged from 12 to 41 percent [<a href="#rid74">74,76,77</a>]. The patients included in these studies were exposed to cumulative doses ranging from 50 to 100 g.</p><p>By contrast, newer CYC regimens of intravenous CYC have markedly reduced the cumulative exposure to CYC, resulting in lower rates of hemorrhagic cystitis [<a href="#rid75">75</a>].</p><p>Few cases of hemorrhagic cystitis have been reported from clinical trials and case reports of patients treated with intermittent intravenous CYC for rheumatic diseases [<a href="#rid75">75</a>]. In a retrospective analysis of 1018 patients treated for autoimmune disease and vasculitis from 13 rheumatology centers, the median CYC dose was 9 g (range 1.5 to 180), and CYC was administered exclusively intravenously in 91 percent, exclusively orally in 5 percent, and by both routes in 4 percent [<a href="#rid78">78</a>]. Overall, only 17 patients were identified with hemorrhagic cystitis (1.67 percent), and the incidence was similar in patients treated with and without <a class="drug drug_general" data-topicid="9615" href="/d/drug information/9615.html" rel="external">mesna</a> (9 of 585 versus 8 of 424, 1.5 versus 1.9 percent). Cumulative dose was associated with hemorrhagic cystitis (hazard ratio [HR] for each 10 g increment 1.24, 95% CI 1.12-1.38). The use of mesna in patients receiving intermittent intravenous CYC for rheumatologic disorders is discussed separately. (See  <a class="medical medical_review" href="/d/html/7963.html" rel="external">"General principles of the use of cyclophosphamide in rheumatic diseases", section on 'Prevention of drug-induced cystitis'</a>.)</p><p>Another potential contributory factor for hemorrhagic cystitis in these patients may be BK virus (human polyomavirus 1). BK virus has been recognized in renal transplant populations as playing a role as a cofactor in cases of drug-induced cystitis [<a href="#rid79">79</a>]. This virus is present in its latent form in the majority of adults and can be reactivated, usually in the urogenital tract, during immunosuppression (see  <a class="medical medical_review" href="/d/html/8280.html" rel="external">"Overview and virology of JC polyomavirus, BK polyomavirus, and other polyomavirus infections"</a>). While the risk of BK infection in nontransplanted immunosuppressed patients has not been well-described, there is reasonable concern for an increased risk of infection among patients with rheumatic diseases treated with CYC [<a href="#rid80">80,81</a>].</p><p class="headingAnchor" id="H96055813"><span class="h3">Bladder cancer</span><span class="headingEndMark"> — </span>Treatment with oral CYC confers an increased, and likely dose-dependent, risk of bladder cancer that may be sustained for years after discontinuation. As an example, a retrospective study of 145 GPA patients treated with oral CYC for at least one year found a 4.8 and 16 percent incidence of bladder cancer after a median follow-up period of 8.5 and 15 years, respectively [<a href="#rid76">76</a>]. Approximately 65 percent of these patients received total doses of more than 50 g. All of the patients who developed bladder cancer had had one or more episodes of microscopic or macroscopic nonglomerular hematuria, and all had been treated for at least 2.7 years.</p><p>In a population based cohort study, after a median of 8 years of follow-up, of 195 patients with history of CYC therapy for ANCA-associated vasculitis, it was reported that 5 patients developed bladder cancer, 3 with a cumulative CYC dose over 10 g and 2 with less than 10 g, leading to an overall sex- and age-adjusted standardized incidence ratio of 4.30 (95% CI 1.40–10.04) over the expected rate [<a href="#rid73">73</a>].</p><p>The risk of secondary bladder cancer increases markedly after an episode of hemorrhagic cystitis. The risk of bladder cancer is also dose related and approaches 5 to 10 percent by five years in patients receiving cumulative doses of CYC ≥30 g, with new cases occurring for up to 20 years [<a href="#rid82">82</a>]. Bladder cancer has developed as little as seven months after starting CYC therapy and as many as 15 or more years after discontinuing the medication [<a href="#rid16">16,71,76</a>].</p><p>Bladder tumors induced by CYC can be particularly aggressive biologically. As an example, a study of 12 cases, found that all of the tumors were grade 3 or 4 transitional cell carcinomas at presentation [<a href="#rid83">83</a>].</p><p>Our approach to surveillance for bladder cancer in patients who have received CYC is discussed separately. (See  <a class="medical medical_review" href="/d/html/2977.html" rel="external">"Screening for bladder cancer"</a>.)</p><p class="headingAnchor" id="H18"><span class="h2">Hyponatremia due to SIADH</span><span class="headingEndMark"> — </span>Intravenous pulse CYC can induce hyponatremia due to the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Marked water retention and potentially fatal hyponatremia can occur, because patients receiving this regimen are treated with intravenous fluids to prevent drug-induced cystitis [<a href="#rid84">84</a>]. SIADH has been described primarily with doses in the range of 30 to 50 mg/kg, typical of those used to treat cancer. SIADH can also occur with the somewhat lower doses (10 to 15 mg/kg) used to treat inflammatory disorders [<a href="#rid84">84-87</a>]. (See  <a class="medical medical_review" href="/d/html/2384.html" rel="external">"Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)", section on 'Drugs'</a>.)</p><p>Hyponatremia can be minimized in this setting by using isotonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> (or half normal saline in patients with edema) rather than free water to maintain a high urine output [<a href="#rid87">87</a>]. (See  <a class="medical medical_review" href="/d/html/2357.html" rel="external">"Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat", section on 'Therapies to raise the serum sodium'</a>.)</p><p class="headingAnchor" id="H19"><span class="h2">Miscellaneous</span><span class="headingEndMark"> — </span>Several other side effects can also be induced by alkylating agent therapy:</p><p class="bulletIndent1"><span class="glyph">●</span>Nausea is common, especially with intravenous CYC [<a href="#rid88">88</a>]. (See  <a class="medical medical_review" href="/d/html/7963.html" rel="external">"General principles of the use of cyclophosphamide in rheumatic diseases", section on 'Intermittent (pulse) cyclophosphamide'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hair loss may occur, although it is generally not as severe as that seen with cancer chemotherapy. The most common pattern is diffuse thinning, which is generally reversible upon discontinuation of the drug. Patients can be told that, although they may note hair thinning that ranges from mild to substantial, all of their hair will not fall out (in contrast to patients treated with cancer chemotherapy doses of CYC). This is particularly true if circumscribed courses (three to six months) of CYC are used. Among patients receiving CYC for membranous nephropathy, 10 percent reported alopecia [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pulmonary fibrosis is a rare complication of CYC. (See  <a class="medical medical_review" href="/d/html/4349.html" rel="external">"Cyclophosphamide pulmonary toxicity"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cardiac toxicity is a major problem in oncology patients treated with higher dose regimens (see  <a class="medical medical_review" href="/d/html/2812.html" rel="external">"Cardiotoxicity of cancer chemotherapy agents other than anthracyclines, HER2-targeted agents, and fluoropyrimidines", section on 'Cyclophosphamide'</a>). For patients with systemic rheumatic diseases treated with CYC, doses may need to be attenuated, and heart function may need to be followed closely if there is decreased myocardial contractility at baseline.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Both hepatotoxicity [<a href="#rid89">89</a>] and anaphylaxis [<a href="#rid90">90</a>] due to CYC are rare. (See  <a class="medical medical_review" href="/d/html/2837.html" rel="external">"Chemotherapy hepatotoxicity and dose modification in patients with liver disease: Conventional cytotoxic agents", section on 'Cyclophosphamide'</a>.)</p><p></p><p class="headingAnchor" id="H728046897"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/120032.html" rel="external">"Society guideline links: Side effects of anti-inflammatory and anti-rheumatic drugs"</a>.)</p><p class="headingAnchor" id="H20"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>The alkylating agent <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> (CYC) exerts its biologic activity via covalent binding and crosslinking of a variety of macromolecules including DNA, RNA, and proteins. (See <a class="local">'Mechanism of action'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The major risk of toxicity from CYC is related to the cumulative dose of the medication. Therefore, strategies that reduce the duration of exposure can minimize the long-term risks. The standard of care for most inflammatory diseases is to induce remission with courses of CYC lasting not longer than six months and then to switch to a less toxic medication for remission maintenance. (See  <a class="medical medical_review" href="/d/html/3105.html" rel="external">"Granulomatosis with polyangiitis and microscopic polyangiitis: Induction and maintenance therapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The principal toxicities of CYC relate to its effects on bone marrow, reproductive organs, and bladder. Long-term concerns relate to the induction of malignancy of many different types. (See <a class="local">'Toxicity'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Specific forms of CYC toxicity include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hematologic toxicity (see <a class="local">'Hematologic toxicity'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Infection (see <a class="local">'Infection'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Infertility (see <a class="local">'Female gonadal toxicity'</a> above and <a class="local">'Male gonadal toxicity'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Adverse effects on pregnancy (see <a class="local">'Teratogenicity'</a> above and  <a class="medical medical_review" href="/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation", section on 'Cyclophosphamide'</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Malignancy induction (see <a class="local">'Malignancy'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Bladder toxicity (see <a class="local">'Bladder toxicity'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Hyponatremia due to the syndrome of inappropriate antidiuretic hormone secretion (SIADH) (see <a class="local">'Hyponatremia due to SIADH'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Several other side effects such as nausea, hair loss, pulmonary fibrosis, cardiac toxicity, and hepatotoxicity (see <a class="local">'Miscellaneous'</a> above)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983; 98:76.</a></li><li><a class="nounderline abstract_t">de Groot K, Harper L, Jayne DR, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009; 150:670.</a></li><li><a class="nounderline abstract_t">Houssiau FA, Vasconcelos C, D'Cruz D, et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 2010; 69:61.</a></li><li><a class="nounderline abstract_t">Hall AG, Tilby MJ. Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies. Blood Rev 1992; 6:163.</a></li><li><a class="nounderline abstract_t">Clements PJ, Yu DT, Levy J, et al. Effects of cyclophosphamide on B- and T-lymphocytes in rheumatoid arthritis. Arthritis Rheum 1974; 17:347.</a></li><li><a class="nounderline abstract_t">McCune WJ, Golbus J, Zeldes W, et al. Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus. N Engl J Med 1988; 318:1423.</a></li><li><a class="nounderline abstract_t">Cupps TR, Edgar LC, Fauci AS. Suppression of human B lymphocyte function by cyclophosphamide. J Immunol 1982; 128:2453.</a></li><li><a class="nounderline abstract_t">Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004; 350:971.</a></li><li><a class="nounderline abstract_t">Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349:36.</a></li><li><a class="nounderline abstract_t">Ekhart C, Rodenhuis S, Smits PH, et al. Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin. Pharmacogenet Genomics 2008; 18:1009.</a></li><li><a class="nounderline abstract_t">Takada K, Arefayene M, Desta Z, et al. Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. Arthritis Rheum 2004; 50:2202.</a></li><li><a class="nounderline abstract_t">Schirmer JH, Bremer JP, Moosig F, et al. Cyclophosphamide treatment-induced leukopenia rates in ANCA-associated vasculitis are influenced by variant CYP450 2C9 genotypes. Pharmacogenomics 2016; 17:367.</a></li><li><a class="nounderline abstract_t">Qiu TT, Zhang C, Zhao HW, Zhou JW. Calcineurin inhibitors versus cyclophosphamide for idiopathic membranous nephropathy: A systematic review and meta-analysis of 21 clinical trials. Autoimmun Rev 2017; 16:136.</a></li><li><a class="nounderline abstract_t">Zhang X, Ji L, Yang L, et al. The effect of calcineurin inhibitors in the induction and maintenance treatment of lupus nephritis: a systematic review and meta-analysis. Int Urol Nephrol 2016; 48:731.</a></li><li><a class="nounderline abstract_t">Mok CC, Ying KY, Ng WL, et al. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide. Am J Med 2006; 119:355.e25.</a></li><li><a class="nounderline abstract_t">Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116:488.</a></li><li><a class="nounderline abstract_t">de Groot K, Adu D, Savage CO, EUVAS (European vasculitis study group). The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant 2001; 16:2018.</a></li><li><a class="nounderline abstract_t">Gourley MF, Austin HA 3rd, Scott D, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 1996; 125:549.</a></li><li><a class="nounderline abstract_t">Boumpas DT, Austin HA 3rd, Vaughn EM, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992; 340:741.</a></li><li><a class="nounderline abstract_t">Huynh-Do U, Gantenbein H, Binswanger U. Pneumocystis carinii pneumonia during immunosuppressive therapy for antineutrophil cytoplasmic autoantibody-positive vasculitis. Arch Intern Med 1995; 155:872.</a></li><li><a class="nounderline abstract_t">Jarrousse B, Guillevin L, Bindi P, et al. Increased risk of Pneumocystis carinii pneumonia in patients with Wegener's granulomatosis. Clin Exp Rheumatol 1993; 11:615.</a></li><li><a class="nounderline abstract_t">Pryor BD, Bologna SG, Kahl LE. Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus. Arthritis Rheum 1996; 39:1475.</a></li><li><a class="nounderline abstract_t">Thong KM, Chan TM. Infectious complications in lupus nephritis treatment: a systematic review and meta-analysis. Lupus 2019; 28:334.</a></li><li><a class="nounderline abstract_t">Lote H, Sharp A, Redana S, et al. Febrile Neutropenia Rates According to Body Mass Index and Dose Capping in Women Receiving Chemotherapy for Early Breast Cancer. Clin Oncol (R Coll Radiol) 2016; 28:597.</a></li><li><a class="nounderline abstract_t">Renehan AG, Harvie M, Cutress RI, et al. How to Manage the Obese Patient With Cancer. J Clin Oncol 2016; 34:4284.</a></li><li><a class="nounderline abstract_t">Griggs JJ, Mangu PB, Anderson H, et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2012; 30:1553.</a></li><li><a class="nounderline abstract_t">Austin HA 3rd, Klippel JH, Balow JE, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314:614.</a></li><li><a class="nounderline abstract_t">Vernovsky I, Dellaripa PF. Pneumocystis carinii pneumonia prophylaxis in patients with rheumatic diseases undergoing immunosuppressive therapy: prealence and associated features. J Clin Rheumatol 2000; 6:94.</a></li><li><a class="nounderline abstract_t">Wung PK, Holbrook JT, Hoffman GS, et al. Herpes zoster in immunocompromised patients: incidence, timing, and risk factors. Am J Med 2005; 118:1416.</a></li><li><a class="nounderline abstract_t">Hu SC, Yen FL, Wang TN, et al. Immunosuppressive medication use and risk of herpes zoster (HZ) in patients with systemic lupus erythematosus (SLE): A nationwide case-control study. J Am Acad Dermatol 2016; 75:49.</a></li><li><a class="nounderline abstract_t">Ferreira JC, Marques HH, Ferriani MP, et al. Herpes zoster infection in childhood-onset systemic lupus erythematosus patients: A large multicenter study. Lupus 2016; 25:754.</a></li><li><a class="nounderline abstract_t">Ognenovski VM, Marder W, Somers EC, et al. Increased incidence of cervical intraepithelial neoplasia in women with systemic lupus erythematosus treated with intravenous cyclophosphamide. J Rheumatol 2004; 31:1763.</a></li><li><a class="nounderline abstract_t">Boumpas DT, Austin HA 3rd, Vaughan EM, et al. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 1993; 119:366.</a></li><li><a class="nounderline abstract_t">Rivkees SA, Crawford JD. The relationship of gonadal activity and chemotherapy-induced gonadal damage. JAMA 1988; 259:2123.</a></li><li><a class="nounderline abstract_t">Watson AR, Taylor J, Rance CP, Bain J. Gonadal function in women treated with cyclophosphamide for childhood nephrotic syndrome: a long-term follow-up study. Fertil Steril 1986; 46:331.</a></li><li><a class="nounderline abstract_t">Wang CL, Wang F, Bosco JJ. Ovarian failure in oral cyclophosphamide treatment for systemic lupus erythematosus. Lupus 1995; 4:11.</a></li><li><a class="nounderline abstract_t">Huong DL, Amoura Z, Duhaut P, et al. Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients. J Rheumatol 2002; 29:2571.</a></li><li><a class="nounderline abstract_t">Clowse ME, Copland SC, Hsieh TC, et al. Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener's). Arthritis Care Res (Hoboken) 2011; 63:1777.</a></li><li><a class="nounderline abstract_t">Harward LE, Mitchell K, Pieper C, et al. The impact of cyclophosphamide on menstruation and pregnancy in women with rheumatologic disease. Lupus 2013; 22:81.</a></li><li><a class="nounderline abstract_t">Luong SN, Isaacs A, Liu Z, et al. A systematic review and meta-analysis of the gonadotoxic effects of cyclophosphamide and benefits of gonadotropin releasing hormone agonists (GnRHa) in women of child-bearing age with autoimmune rheumatic disease. Expert Rev Clin Immunol 2020; 16:321.</a></li><li><a class="nounderline abstract_t">Tamirou F, Husson SN, Gruson D, et al. Brief report: The Euro-lupus low-dose intravenous cyclophosphamide regimen does not impact the ovarian reserve, as measured by serum levels of anti-Müllerian hormone. Arthritis Rheumatol 2017; 69:1267.</a></li><li><a class="nounderline abstract_t">Ramsey-Goldman R, Mientus JM, Kutzer JE, et al. Pregnancy outcome in women with systemic lupus erythematosus treated with immunosuppressive drugs. J Rheumatol 1993; 20:1152.</a></li><li><a class="nounderline abstract_t">Morel N, Bachelot A, Chakhtoura Z, et al. Study of anti-Müllerian hormone and its relation to the subsequent probability of pregnancy in 112 patients with systemic lupus erythematosus, exposed or not to cyclophosphamide. J Clin Endocrinol Metab 2013; 98:3785.</a></li><li><a class="nounderline abstract_t">Alarfaj AS, Khalil N. Fertility, ovarian failure, and pregnancy outcome in SLE patients treated with intravenous cyclophosphamide in Saudi Arabia. Clin Rheumatol 2014; 33:1731.</a></li><li><a class="nounderline abstract_t">Watson AR, Rance CP, Bain J. Long term effects of cyclophosphamide on testicular function. Br Med J (Clin Res Ed) 1985; 291:1457.</a></li><li><a class="nounderline abstract_t">Guesry P, Lenoir G, Broyer M. Gonadal effects of chlorambucil given to prepubertal and pubertal boys for nephrotic syndrome. J Pediatr 1978; 92:299.</a></li><li><a class="nounderline abstract_t">Jahnukainen K, Ehmcke J, Hou M, Schlatt S. Testicular function and fertility preservation in male cancer patients. Best Pract Res Clin Endocrinol Metab 2011; 25:287.</a></li><li><a class="nounderline abstract_t">Fukutani K, Ishida H, Shinohara M, et al. Suppression of spermatogenesis in patients with Behçet's disease treated with cyclophosphamide and colchicine. Fertil Steril 1981; 36:76.</a></li><li><a class="nounderline abstract_t">Bogdanović R, Banićević M, Cvorić A. Testicular function following cyclophosphamide treatment for childhood nephrotic syndrome: long-term follow-up study. Pediatr Nephrol 1990; 4:451.</a></li><li><a class="nounderline abstract_t">Hoorweg-Nijman JJ, Delemarre-van de Waal HA, de Waal FC, Behrendt H. Cyclophosphamide-induced disturbance of gonadotropin secretion manifesting testicular damage. Acta Endocrinol (Copenh) 1992; 126:143.</a></li><li><a class="nounderline abstract_t">Soares PM, Borba EF, Bonfa E, et al. Gonad evaluation in male systemic lupus erythematosus. Arthritis Rheum 2007; 56:2352.</a></li><li><a class="nounderline abstract_t">Kirshon B, Wasserstrum N, Willis R, et al. Teratogenic effects of first-trimester cyclophosphamide therapy. Obstet Gynecol 1988; 72:462.</a></li><li><a class="nounderline abstract_t">Murray CL, Reichert JA, Anderson J, Twiggs LB. Multimodal cancer therapy for breast cancer in the first trimester of pregnancy. A case report. JAMA 1984; 252:2607.</a></li><li><a class="nounderline abstract_t">Wiebe VJ, Sipila PE. Pharmacology of antineoplastic agents in pregnancy. Crit Rev Oncol Hematol 1994; 16:75.</a></li><li><a class="nounderline abstract_t">Clowse ME, Magder L, Petri M. Cyclophosphamide for lupus during pregnancy. Lupus 2005; 14:593.</a></li><li><a class="nounderline abstract_t">Götestam Skorpen C, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 2016; 75:795.</a></li><li><a class="nounderline abstract_t">Enns GM, Roeder E, Chan RT, et al. Apparent cyclophosphamide (cytoxan) embryopathy: a distinct phenotype? Am J Med Genet 1999; 86:237.</a></li><li><a class="nounderline abstract_t">Vaux KK, Kahole NC, Jones KL. Cyclophosphamide, methotrexate, and cytarabine embropathy: is apoptosis the common pathway? Birth Defects Res A Clin Mol Teratol 2003; 67:403.</a></li><li><a class="nounderline abstract_t">Paladini D, Vassallo M, D'Armiento MR, et al. Prenatal detection of multiple fetal anomalies following inadvertent exposure to cyclophosphamide in the first trimester of pregnancy. Birth Defects Res A Clin Mol Teratol 2004; 70:99.</a></li><li><a class="nounderline abstract_t">Paskulin GA, Gazzola Zen PR, de Camargo Pinto LL, et al. Combined chemotherapy and teratogenicity. Birth Defects Res A Clin Mol Teratol 2005; 73:634.</a></li><li><a class="nounderline abstract_t">Zemlickis D, Lishner M, Erlich R, Koren G. Teratogenicity and carcinogenicity in a twin exposed in utero to cyclophosphamide. Teratog Carcinog Mutagen 1993; 13:139.</a></li><li><a class="nounderline abstract_t">Berry DL, Theriault RL, Holmes FA, et al. Management of breast cancer during pregnancy using a standardized protocol. J Clin Oncol 1999; 17:855.</a></li><li><a class="nounderline abstract_t">Passera S, Contarino V, Scarfone G, et al. Effects of in-utero exposure to chemotherapy on fetal brain growth. Int J Gynecol Cancer 2019; 29:1195.</a></li><li><a class="nounderline abstract_t">Kart Köseoglu H, Yücel AE, Künefeci G, et al. Cyclophosphamide therapy in a serious case of lupus nephritis during pregnancy. Lupus 2001; 10:818.</a></li><li><a class="nounderline abstract_t">Trasler JM, Hales BF, Robaire B. Paternal cyclophosphamide treatment of rats causes fetal loss and malformations without affecting male fertility. Nature 1985; 316:144.</a></li><li><a class="nounderline abstract_t">Romerius P, Ståhl O, Moëll C, et al. Sperm DNA integrity in men treated for childhood cancer. Clin Cancer Res 2010; 16:3843.</a></li><li><a class="nounderline abstract_t">Tolchin SF, Winkelstein A, Rodnan GP, et al. Chromosome abnormalities from cyclophosphamide therapy in rheumatoid arthritis and progressive systemic sclerosis (scleroderma). Arthritis Rheum 1974; 17:375.</a></li><li><a class="nounderline abstract_t">Russell JA, Powles RL, Oliver RT. Conception and congenital abnormalities after chemotherapy of acute myelogenous leukaemia in two men. Br Med J 1976; 1:1508.</a></li><li><a class="nounderline abstract_t">Lohrmann HP. The problem of permanent bone marrow damage after cytotoxic drug treatment. Oncology 1984; 41:180.</a></li><li><a class="nounderline abstract_t">Vasquez S, Kavanaugh AF, Schneider NR, et al. Acute nonlymphocytic leukemia after treatment of systemic lupus erythematosus with immunosuppressive agents. J Rheumatol 1992; 19:1625.</a></li><li><a class="nounderline abstract_t">Radis CD, Kahl LE, Baker GL, et al. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study. Arthritis Rheum 1995; 38:1120.</a></li><li><a class="nounderline abstract_t">Bernatsky S, Clarke AE, Suissa S. Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis. Arch Intern Med 2008; 168:378.</a></li><li><a class="nounderline abstract_t">Heijl C, Westman K, Höglund P, Mohammad AJ. Malignancies in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitis: A Population-based Cohort Study. J Rheumatol 2020; 47:1229.</a></li><li><a class="nounderline abstract_t">Reinhold-Keller E, Beuge N, Latza U, et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 2000; 43:1021.</a></li><li><a class="nounderline abstract_t">Monach PA, Arnold LM, Merkel PA. Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review. Arthritis Rheum 2010; 62:9.</a></li><li><a class="nounderline abstract_t">Talar-Williams C, Hijazi YM, Walther MM, et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 1996; 124:477.</a></li><li><a class="nounderline abstract_t">Stillwell TJ, Benson RC Jr, DeRemee RA, et al. Cyclophosphamide-induced bladder toxicity in Wegener's granulomatosis. Arthritis Rheum 1988; 31:465.</a></li><li><a class="nounderline abstract_t">Yilmaz N, Emmungil H, Gucenmez S, et al. Incidence of Cyclophosphamide-induced Urotoxicity and Protective Effect of Mesna in Rheumatic Diseases. J Rheumatol 2015; 42:1661.</a></li><li><a class="nounderline abstract_t">Bedi A, Miller CB, Hanson JL, et al. Association of BK virus with failure of prophylaxis against hemorrhagic cystitis following bone marrow transplantation. J Clin Oncol 1995; 13:1103.</a></li><li><a class="nounderline abstract_t">Gupta N, Lawrence RM, Nguyen C, Modica RF. Review article: BK virus in systemic lupus erythematosus. Pediatr Rheumatol Online J 2015; 13:34.</a></li><li><a class="nounderline abstract_t">Umeda M, Ichinose K, Okada A, et al. A rare case of hemorrhagic cystitis complicated with thrombocytopenia and hemophagocytic syndrome associated with BK virus, under immunosuppressive treatment of systemic lupus erythematosus. Mod Rheumatol 2016; 26:467.</a></li><li><a class="nounderline abstract_t">Baker GL, Kahl LE, Zee BC, et al. Malignancy following treatment of rheumatoid arthritis with cyclophosphamide. Long-term case-control follow-up study. Am J Med 1987; 83:1.</a></li><li><a class="nounderline abstract_t">Fernandes ET, Manivel JC, Reddy PK, Ercole CJ. Cyclophosphamide associated bladder cancer--a highly aggressive disease: analysis of 12 cases. J Urol 1996; 156:1931.</a></li><li><a class="nounderline abstract_t">Bressler RB, Huston DP. Water intoxication following moderate-dose intravenous cyclophosphamide. Arch Intern Med 1985; 145:548.</a></li><li><a class="nounderline abstract_t">Salido M, Macarron P, Hernández-García C, et al. Water intoxication induced by low-dose cyclophosphamide in two patients with systemic lupus erythematosus. Lupus 2003; 12:636.</a></li><li><a class="nounderline abstract_t">Spital A, Ristow S. Cyclophosphamide induced water intoxication in a woman with Sjögren's syndrome. J Rheumatol 1997; 24:2473.</a></li><li><a class="nounderline abstract_t">Lee YC, Park JS, Lee CH, et al. Hyponatraemia induced by low-dose intravenous pulse cyclophosphamide. Nephrol Dial Transplant 2010; 25:1520.</a></li><li><a class="nounderline abstract_t">Singh G, Fries JF, Williams CA, et al. Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis. J Rheumatol 1991; 18:188.</a></li><li><a class="nounderline abstract_t">Subramaniam SR, Cader RA, Mohd R, et al. Low-dose cyclophosphamide-induced acute hepatotoxicity. Am J Case Rep 2013; 14:345.</a></li><li><a class="nounderline abstract_t">Garas G, Crawford GP, Cain M. Anaphylactic reaction to intravenous cyclophosphamide. Aust N Z J Med 1995; 25:59.</a></li></ol></div><div id="topicVersionRevision">Topic 7987 Version 27.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6336643" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19451574" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19155235" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1422285" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4136699" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Effects of cyclophosphamide on B- and T-lymphocytes in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3259286" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6978904" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Suppression of human B lymphocyte function by cyclophosphamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14999109" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Sequential therapies for proliferative lupus nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12840090" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18854779" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15248218" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26894931" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Cyclophosphamide treatment-induced leukopenia rates in ANCA-associated vasculitis are influenced by variant CYP450 2C9 genotypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27988429" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Calcineurin inhibitors versus cyclophosphamide for idiopathic membranous nephropathy: A systematic review and meta-analysis of 21 clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26781720" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The effect of calcineurin inhibitors in the induction and maintenance treatment of lupus nephritis: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16564783" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1739240" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Wegener granulomatosis: an analysis of 158 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11572891" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8815753" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1356175" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7717797" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Pneumocystis carinii pneumonia during immunosuppressive therapy for antineutrophil cytoplasmic autoantibody-positive vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8299252" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Increased risk of Pneumocystis carinii pneumonia in patients with Wegener's granulomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8814058" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30744523" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Infectious complications in lupus nephritis treatment: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26936608" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Febrile Neutropenia Rates According to Body Mass Index and Dose Capping in Women Receiving Chemotherapy for Early Breast Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27903151" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : How to Manage the Obese Patient With Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22473167" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3511372" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19078457" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Pneumocystis carinii pneumonia prophylaxis in patients with rheumatic diseases undergoing immunosuppressive therapy: prealence and associated features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16378799" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Herpes zoster in immunocompromised patients: incidence, timing, and risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26946984" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Immunosuppressive medication use and risk of herpes zoster (HZ) in patients with systemic lupus erythematosus (SLE): A nationwide case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26821966" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Herpes zoster infection in childhood-onset systemic lupus erythematosus patients: A large multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15338497" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Increased incidence of cervical intraepithelial neoplasia in women with systemic lupus erythematosus treated with intravenous cyclophosphamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8338289" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3162285" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The relationship of gonadal activity and chemotherapy-induced gonadal damage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3732541" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Gonadal function in women treated with cyclophosphamide for childhood nephrotic syndrome: a long-term follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7767332" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Ovarian failure in oral cyclophosphamide treatment for systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12465154" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22127969" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener's).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23263867" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The impact of cyclophosphamide on menstruation and pregnancy in women with rheumatologic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32005081" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : A systematic review and meta-analysis of the gonadotoxic effects of cyclophosphamide and benefits of gonadotropin releasing hormone agonists (GnRHa) in women of child-bearing age with autoimmune rheumatic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28235250" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Brief report: The Euro-lupus low-dose intravenous cyclophosphamide regimen does not impact the ovarian reserve, as measured by serum levels of anti-Müllerian hormone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8371208" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Pregnancy outcome in women with systemic lupus erythematosus treated with immunosuppressive drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23833039" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Study of anti-Müllerian hormone and its relation to the subsequent probability of pregnancy in 112 patients with systemic lupus erythematosus, exposed or not to cyclophosphamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24894105" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Fertility, ovarian failure, and pregnancy outcome in SLE patients treated with intravenous cyclophosphamide in Saudi Arabia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3933709" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Long term effects of cyclophosphamide on testicular function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/621613" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Gonadal effects of chlorambucil given to prepubertal and pubertal boys for nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21397199" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Testicular function and fertility preservation in male cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6788612" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Suppression of spermatogenesis in patients with Behçet's disease treated with cyclophosphamide and colchicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2242303" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Testicular function following cyclophosphamide treatment for childhood nephrotic syndrome: long-term follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1311893" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Cyclophosphamide-induced disturbance of gonadotropin secretion manifesting testicular damage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17599762" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Gonad evaluation in male systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3136412" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Teratogenic effects of first-trimester cyclophosphamide therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6092731" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Multimodal cancer therapy for breast cancer in the first trimester of pregnancy. A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8068213" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Pharmacology of antineoplastic agents in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16175930" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Cyclophosphamide for lupus during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26888948" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10482872" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Apparent cyclophosphamide (cytoxan) embryopathy: a distinct phenotype?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12962283" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Cyclophosphamide, methotrexate, and cytarabine embropathy: is apoptosis the common pathway?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14991918" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Prenatal detection of multiple fetal anomalies following inadvertent exposure to cyclophosphamide in the first trimester of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16104005" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Combined chemotherapy and teratogenicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8105555" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Teratogenicity and carcinogenicity in a twin exposed in utero to cyclophosphamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10071276" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Management of breast cancer during pregnancy using a standardized protocol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31395614" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Effects of in-utero exposure to chemotherapy on fetal brain growth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11789493" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Cyclophosphamide therapy in a serious case of lupus nephritis during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4040213" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Paternal cyclophosphamide treatment of rats causes fetal loss and malformations without affecting male fertility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20519359" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Sperm DNA integrity in men treated for childhood cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4851019" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Chromosome abnormalities from cyclophosphamide therapy in rheumatoid arthritis and progressive systemic sclerosis (scleroderma).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1064461" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Conception and congenital abnormalities after chemotherapy of acute myelogenous leukaemia in two men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6374556" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : The problem of permanent bone marrow damage after cytotoxic drug treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1464880" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Acute nonlymphocytic leukemia after treatment of systemic lupus erythematosus with immunosuppressive agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7639809" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18299492" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31474595" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Malignancies in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitis: A Population-based Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10817555" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20039416" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8602705" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3358809" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Cyclophosphamide-induced bladder toxicity in Wegener's granulomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26178288" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Incidence of Cyclophosphamide-induced Urotoxicity and Protective Effect of Mesna in Rheumatic Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7738616" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Association of BK virus with failure of prophylaxis against hemorrhagic cystitis following bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26293687" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Review article: BK virus in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26011441" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : A rare case of hemorrhagic cystitis complicated with thrombocytopenia and hemophagocytic syndrome associated with BK virus, under immunosuppressive treatment of systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3605161" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Malignancy following treatment of rheumatoid arthritis with cyclophosphamide. Long-term case-control follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8911359" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Cyclophosphamide associated bladder cancer--a highly aggressive disease: analysis of 12 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3977522" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Water intoxication following moderate-dose intravenous cyclophosphamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12945725" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Water intoxication induced by low-dose cyclophosphamide in two patients with systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9415661" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Cyclophosphamide induced water intoxication in a woman with Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20007128" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Hyponatraemia induced by low-dose intravenous pulse cyclophosphamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1673721" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24023976" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Low-dose cyclophosphamide-induced acute hepatotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7786253" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Anaphylactic reaction to intravenous cyclophosphamide.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
